Ranbaxy loses early bid to block generic competition
This article was originally published in Scrip
Executive Summary
Ranbaxy has suffered an early setback in its challenge to the FDA's decision to revoke tentative approvals for its ANDAs for generic versions of AstraZeneca's Nexium (esomeprazole magnesium) and Roche's Valcyte (valganciclovir hydrochloride), after a US court declined to hold back competition for the products.